Top healthcare mergers and acquisitions in November 2026
Every verified merger and acquisition in the healthcare sector in this period, ranked by disclosed value. Updated every morning.
We tracked 7 deals in the healthcare sector in November 2026, 5 of them with a disclosed value, worth $6.1bn in total. The largest was Indivior Pharmaceuticals, Inc.'s $3.4bn deal for Supernus Pharmaceuticals, Inc., ahead of Samsung Biologics and PolyPeptide Group AG at $1.8bn.
Top healthcare mergers and acquisitions in November 2026
- 12 NovIndivior Pharmaceuticals, Inc. → Supernus Pharmaceuticals, Inc.Indivior and Supernus complete merger to form CNS drugmakerHealthcare / CNS pharmaceuticalsCompleted$3.4bn
- 22 NovSamsung Biologics → PolyPeptide Group AGSamsung secures 98% of PolyPeptide as offer awaits final clearancesHealthcare / Pharma CDMOIn review$1.8bn
- 35 NovANI Pharmaceuticals, Inc. → Egetis Therapeutics AB (publ)ANI Pharmaceuticals bids SEK 5.3bn for rare disease drugmaker EgetisHealthcare / Rare disease pharmaceuticalsAgreed$540m
- 44 NovAgilent Technologies → ProsciaAgilent completes US$240m acquisition of ProsciaHealthcare / Digital pathology softwareCompleted$240m
- 53 NovRockwell Medical, Inc. → Vantive's in-centre hemodialysis businessRockwell Medical to buy Vantive's hemodialysis businessHealthcare / Medical devicesAgreed$125m
- 63 NovCinven → TheramexCinven agrees to buy women's health drugmaker Theramex from Carlyle and PAIHealthcare / Specialty pharmaceuticalsAgreedUndisclosed
- 72 NovAyrmid Ltd. → Karyopharm Therapeutics Inc.Karyopharm files for Chapter 11 with Ayrmid merger planHealthcare / BiotechAnnouncedUndisclosed